Upon completion of the educational activity, participants should be better able to:
Explain the complex relationships between insulin resistance and CKD, discuss the underlying mechanisms driving CVD development and progression, and apply a comprehensive framework for risk stratification and prevention of CVD in patients with these comorbidities.
Identify and apply evidence-based risk assessment strategies for CVD in patients with metabolic risk factors, hypertension, diabetes, CKD, or a combination of these, using tools such as risk calculators and biomarkers to facilitate early detection and timely intervention.
Identify guideline-based treatment options for managing CVD in patients with metabolic disease, diabetes, and kidney disease, including lifestyle modifications, emerging and existing pharmacologic interventions such as sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1), anti-hypertensive therapies, and lipid-lowering agents, and digital health technologies.
Apply clear referral criteria to identify patients requiring specialized care, ensuring timely and appropriate referrals to endocrinologists, cardiologists, nephrologists, and other specialists.
Starts 10/31/2024 | Expires 10/31/2025
Starts 10/14/2024 | Expires 10/14/2025
Starts 10/21/2024 | Expires 10/21/2025
Starts 10/7/2024 | Expires 10/7/2025
Starts 10/28/2024 | Expires 10/28/2025
The Kidney in Cardiometabolic Disease session presented at the AACE 2025 Annual Meeting highlights the critical role of kidney function in managing cardiometabolic disorders, such as diabetes, heart failure, and cardiovascular diseases, emphasizing the importance of integrated care approaches through a case-based interactive program format.
The session aims to deepen understanding of how renal dysfunction can influence the progression and management of cardiometabolic diseases, with an emphasis on:
• The pathophysiology of chronic kidney disease within the cardiometabolic spectrum, including age-related changes and mineral-bone disorders.• The impact of renal impairment on cardiovascular risk and metabolic control.• Strategies for early detection and management of renal complications in cardiometabolic patients, including risk assessment considerations for aging populations with declining renal function